| (3S,5R)-fluvastatin | multiple interactions | ISO | RGD:732384 | 6480464 | [zoledronic acid co-treated with fluvastatin] results in increased expression of IGFBP5 mRNA | CTD | PMID:16996129 |
| 1,1,1-trichloro-2,2-bis(4-hydroxyphenyl)ethane | decreases expression | ISO | RGD:10776 | 6480464 | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased expression of IGFBP5 mRNA | CTD | PMID:11509743 |
| 1,1,1-trichloro-2,2-bis(4-hydroxyphenyl)ethane | affects expression | EXP | | 6480464 | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the expression of IGFBP5 mRNA | CTD | PMID:19414516 |
| 1,1,1-trichloro-2,2-bis(4-hydroxyphenyl)ethane | multiple interactions | EXP | | 6480464 | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IGFBP5 mRNA]; more ... | CTD | PMID:19414516 |
| 1,1,1-trichloro-2,2-bis(4-hydroxyphenyl)ethane | multiple interactions | ISO | RGD:10776 | 6480464 | [Estradiol co-treated with 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane] results in decreased expression of IGFBP5 mRNA | CTD | PMID:11509743 |
| 1,10-phenanthroline | decreases degradation | EXP | | 6480464 | 1,10-phenanthroline results in decreased degradation of IGFBP5 protein | CTD | PMID:8894652 |
| 17alpha-ethynylestradiol | increases expression | ISO | RGD:10776 | 6480464 | Ethinyl Estradiol results in increased expression of IGFBP5 mRNA | CTD | PMID:17942748 |
| 17alpha-ethynylestradiol | decreases expression | ISO | RGD:732384 | 6480464 | Ethinyl Estradiol results in decreased expression of IGFBP5 mRNA | CTD | PMID:18936297 |
| 17alpha-ethynylestradiol | affects expression | EXP | | 6480464 | Ethinyl Estradiol affects the expression of IGFBP5 mRNA | CTD | PMID:17557909 |
| 17alpha-ethynylestradiol | multiple interactions | ISO | RGD:10776 | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of IGFBP5 mRNA | CTD | PMID:17942748 |
| 17beta-estradiol | affects expression | ISO | RGD:732384 | 6480464 | Estradiol affects the expression of IGFBP5 mRNA | CTD | PMID:21826169 PMID:14699072 |
| 17beta-estradiol | decreases expression | ISO | RGD:732384 | 6480464 | Estradiol results in decreased expression of IGFBP5 mRNA | CTD | PMID:15159206 PMID:21185374 |
| 17beta-estradiol | affects expression | ISO | RGD:732384 | 6480464 | Estradiol affects the expression of IGFBP5 mRNA | CTD | PMID:14699072 PMID:21826169 |
| 17beta-estradiol | increases expression | ISO | RGD:732384 | 6480464 | Estradiol results in increased expression of IGFBP5 mRNA | CTD | PMID:19619570 PMID:17555868 |
| 17beta-estradiol | decreases expression | ISO | RGD:10776 | 6480464 | Estradiol results in decreased expression of IGFBP5 mRNA | CTD | PMID:11509743 |
| 17beta-estradiol | multiple interactions | ISO | RGD:10776 | 6480464 | [Estradiol co-treated with 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane] results in decreased expression of IGFBP5 mRNA; more ... | CTD | PMID:11509743 |
| 17beta-estradiol | increases expression | ISO | RGD:732384 | 6480464 | Estradiol results in increased expression of IGFBP5 mRNA | CTD | PMID:17555868 PMID:19619570 |
| 17beta-estradiol | decreases expression | ISO | RGD:732384 | 6480464 | Estradiol results in decreased expression of IGFBP5 mRNA | CTD | PMID:15159206 |
| 17beta-estradiol | multiple interactions | ISO | RGD:732384 | 6480464 | [Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of IGFBP5 mRNA | CTD | PMID:19619570 |
| 17beta-estradiol | affects expression | ISO | RGD:732384 | 6480464 | Estradiol affects the expression of IGFBP5 mRNA | CTD | PMID:14699072 |
| 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:732384 | 6480464 | [Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of IGFBP5 mRNA | CTD | PMID:19619570 |
| 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:10776 | 6480464 | Tetrachlorodibenzodioxin affects the expression of IGFBP5 mRNA | CTD | PMID:17555868 PMID:21570461 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:732384 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of IGFBP5 mRNA | CTD | PMID:17555868 PMID:19619570 |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:10776 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of IGFBP5 mRNA | CTD | PMID:16054899 |
| 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:10776 | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of IGFBP5 mRNA | CTD | PMID:17942748 |
| 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:10776 | 6480464 | [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of IGFBP5 mRNA]; more ... | CTD | PMID:16054899 |
| 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:10776 | 6480464 | Tetrachlorodibenzodioxin affects the expression of IGFBP5 mRNA | CTD | PMID:17555868 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:732384 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of IGFBP5 mRNA | CTD | PMID:19619570 PMID:17555868 |
| 2,4,6-trinitrobenzenesulfonic acid | increases expression | ISO | RGD:10776 | 6480464 | Trinitrobenzenesulfonic Acid results in increased expression of IGFBP5 mRNA | CTD | PMID:18200517 PMID:17982090 |
| 2,4,6-trinitrobenzenesulfonic acid | increases expression | ISO | RGD:10776 | 6480464 | Trinitrobenzenesulfonic Acid results in increased expression of IGFBP5 mRNA | CTD | PMID:17982090 PMID:18200517 |
| 2,4,6-trinitrobenzenesulfonic acid | multiple interactions | ISO | RGD:10776 | 6480464 | Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IGFBP5 mRNA] | CTD | PMID:18200517 |
| 2-amino-2-deoxy-D-glucopyranose | multiple interactions | EXP | | 6480464 | Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP5 mRNA] | CTD | PMID:17109745 |
| 2-amino-2-deoxy-D-glucopyranose | increases expression | EXP | | 6480464 | Glucosamine results in increased expression of IGFBP5 mRNA | CTD | PMID:17109745 |
| 2-methylcholine | affects expression | ISO | RGD:732384 | 6480464 | beta-methylcholine affects the expression of IGFBP5 mRNA | CTD | PMID:21179406 |
| 3',5'-cyclic AMP | multiple interactions | EXP | | 6480464 | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IGFBP5 mRNA] | CTD | PMID:19414516 |
| 3,4-methylenedioxymethamphetamine | increases expression | ISO | RGD:10776 | 6480464 | N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of IGFBP5 mRNA | CTD | PMID:20188158 |
| 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | RGD:10776 | 6480464 | [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of IGFBP5 mRNA]; more ... | CTD | PMID:16054899 |
| 4-hydroxyphenyl retinamide | decreases expression | ISO | RGD:732384 | 6480464 | Fenretinide results in decreased expression of IGFBP5 mRNA | CTD | PMID:16671099 |
| 4-vinylcyclohexene dioxide | affects expression | ISO | RGD:10776 | 6480464 | 4-vinyl-1-cyclohexene dioxide affects the expression of IGFBP5 mRNA | CTD | PMID:20829426 |
| 5-aza-2'-deoxycytidine | multiple interactions | ISO | RGD:732384 | 6480464 | decitabine inhibits the reaction [monomethylarsonous acid results in decreased expression of IGFBP5 mRNA] | CTD | PMID:16507463 |
| 5-fluorouracil | decreases expression | ISO | RGD:732384 | 6480464 | Fluorouracil results in decreased expression of IGFBP5 mRNA | CTD | PMID:16557594 |
| 8-bromo-3',5'-cyclic AMP | increases expression | ISO | RGD:732384 | 6480464 | 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP5 mRNA | CTD | PMID:22079614 |
| aldehydo-D-glucosamine | increases expression | EXP | | 6480464 | Glucosamine results in increased expression of IGFBP5 mRNA | CTD | PMID:17109745 |
| aldehydo-D-glucosamine | multiple interactions | EXP | | 6480464 | Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP5 mRNA] | CTD | PMID:17109745 |
| all-trans-retinoic acid | increases expression | ISO | RGD:10776 | 6480464 | Tretinoin results in increased expression of IGFBP5 mRNA | CTD | PMID:16604517 |
| all-trans-retinoic acid | decreases expression | ISO | RGD:732384 | 6480464 | Tretinoin results in decreased expression of IGFBP5 mRNA | CTD | PMID:21934132 |
| all-trans-retinoic acid | multiple interactions | ISO | RGD:732384 | 6480464 | [Tretinoin co-treated with Ascorbic Acid] results in decreased expression of IGFBP5 mRNA | CTD | PMID:16443354 |
| aluminium trifluoride | increases expression | ISO | RGD:732384 | 6480464 | aluminum fluoride results in increased expression of IGFBP5 protein; more ... | CTD | PMID:11996908 |
| ammonium chloride | affects expression | EXP | | 6480464 | Ammonium Chloride affects the expression of IGFBP5 mRNA | CTD | PMID:16483693 |
| amphotericin B | decreases expression | ISO | RGD:732384 | 6480464 | Amphotericin B results in decreased expression of IGFBP5 mRNA | CTD | PMID:20849824 |
| benzamidine | decreases degradation | EXP | | 6480464 | benzamidine results in decreased degradation of IGFBP5 protein | CTD | PMID:8894652 |
| benzo[a]pyrene | decreases expression | ISO | RGD:10776 | 6480464 | Benzo(a)pyrene results in decreased expression of IGFBP5 mRNA | CTD | PMID:22610609 |
| beta-D-glucosamine | multiple interactions | EXP | | 6480464 | Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP5 mRNA] | CTD | PMID:17109745 |
| beta-D-glucosamine | increases expression | EXP | | 6480464 | Glucosamine results in increased expression of IGFBP5 mRNA | CTD | PMID:17109745 |
| bicalutamide | increases expression | EXP | | 6480464 | bicalutamide results in increased expression of IGFBP5 mRNA | CTD | PMID:10604720 |
| bis(2-chloroethyl) sulfide | decreases expression | ISO | RGD:10776 | 6480464 | Mustard Gas results in decreased expression of IGFBP5 mRNA | CTD | PMID:15674843 |
| bisphenol A | affects expression | ISO | RGD:732384 | 6480464 | bisphenol A affects the expression of IGFBP5 mRNA | CTD | PMID:21826169 |
| C60 fullerene | decreases expression | EXP | | 6480464 | fullerene C60 results in decreased expression of IGFBP5 mRNA | CTD | PMID:19167457 |
| cadmium dichloride | increases expression | EXP | | 6480464 | Cadmium Chloride results in increased expression of IGFBP5 mRNA | CTD | PMID:15454312 |
| calcitriol | multiple interactions | ISO | RGD:732384 | 6480464 | IGFBP5 protein inhibits the reaction [Calcitriol results in increased expression of COL1A1 protein] | CTD | PMID:17595320 |
| calcium atom | affects expression | EXP | | 6480464 | Calcium affects the expression of IGFBP5 mRNA | CTD | PMID:15913539 |
| calcium atom | decreases degradation | EXP | | 6480464 | Calcium results in decreased degradation of IGFBP5 protein | CTD | PMID:8894652 |
| calcium(0) | decreases degradation | EXP | | 6480464 | Calcium results in decreased degradation of IGFBP5 protein | CTD | PMID:8894652 |
| calcium(0) | affects expression | EXP | | 6480464 | Calcium affects the expression of IGFBP5 mRNA | CTD | PMID:15913539 |
| chloroprene | increases expression | EXP | | 6480464 | Chloroprene results in increased expression of IGFBP5 mRNA | CTD | PMID:23125180 |
| chlorpyrifos | decreases expression | EXP | | 6480464 | Chlorpyrifos results in decreased expression of IGFBP5 mRNA | CTD | PMID:18668222 |
| cisplatin | decreases expression | ISO | RGD:10776 | 6480464 | Cisplatin results in decreased expression of IGFBP5 mRNA | CTD | PMID:21151649 |
| cisplatin | decreases expression | ISO | RGD:732384 | 6480464 | Cisplatin results in decreased expression of IGFBP5 mRNA | CTD | PMID:20849824 |
| cisplatin | affects response to substance | ISO | RGD:732384 | 6480464 | IGFBP5 protein affects the susceptibility to Cisplatin | CTD | PMID:16217747 |
| corticosterone | decreases expression | EXP | | 6480464 | Corticosterone results in decreased expression of IGFBP5 mRNA | CTD | PMID:15755911 |
| cortisol | decreases expression | ISO | RGD:732384 | 6480464 | Hydrocortisone results in decreased expression of IGFBP5 mRNA | CTD | PMID:21267416 |
| coumestrol | multiple interactions | ISO | RGD:732384 | 6480464 | [Coumestrol co-treated with resveratrol] results in decreased expression of IGFBP5 mRNA; more ... | CTD | PMID:19167446 |
| coumestrol | decreases expression | ISO | RGD:732384 | 6480464 | Coumestrol results in decreased expression of IGFBP5 mRNA | CTD | PMID:19167446 |
| curcumin | multiple interactions | ISO | RGD:10776 | 6480464 | Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IGFBP5 mRNA] | CTD | PMID:18200517 |
| cyclophosphamide | decreases expression | ISO | RGD:10776 | 6480464 | Cyclophosphamide results in decreased expression of IGFBP5 mRNA | CTD | PMID:15331540 |
| cyclophosphamide | decreases expression | ISO | RGD:732384 | 6480464 | Cyclophosphamide results in decreased expression of IGFBP5 mRNA | CTD | PMID:20849824 |
| cyclosporin A | increases expression | EXP | | 6480464 | Cyclosporine results in increased expression of IGFBP5 mRNA | CTD | PMID:21865292 |
| cytarabine | decreases expression | ISO | RGD:732384 | 6480464 | Cytarabine results in decreased expression of IGFBP5 mRNA | CTD | PMID:21198554 |
| dasatinib (anhydrous) | increases expression | ISO | RGD:732384 | 6480464 | dasatinib results in increased expression of IGFBP5 mRNA | CTD | PMID:20579391 |
| Delta(9)-tetrahydrocannabinol | decreases expression | EXP | | 6480464 | Tetrahydrocannabinol results in decreased expression of IGFBP5 mRNA | CTD | PMID:17578508 |
| Delta(9)-tetrahydrocannabinol | decreases expression | ISO | RGD:732384 | 6480464 | Tetrahydrocannabinol results in decreased expression of IGFBP5 mRNA | CTD | PMID:18454173 |
| dexamethasone | multiple interactions | ISO | RGD:10776 | 6480464 | [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of IGFBP5 mRNA; more ... | CTD | PMID:16054899 |
| dexamethasone | multiple interactions | EXP | | 6480464 | Testosterone inhibits the reaction [Dexamethasone results in decreased expression of IGFBP5 mRNA] | CTD | PMID:20032058 |
| dexamethasone | decreases expression | EXP | | 6480464 | Dexamethasone results in decreased expression of IGFBP5 mRNA | CTD | PMID:20032058 |
| dibutyl phthalate | decreases expression | EXP | | 6480464 | Dibutyl Phthalate results in decreased expression of IGFBP5 mRNA | CTD | PMID:21266533 |
| dibutyl phthalate | increases expression | EXP | | 6480464 | Dibutyl Phthalate results in increased expression of IGFBP5 mRNA | CTD | PMID:15829613 |
| estriol | decreases expression | ISO | RGD:732384 | 6480464 | Estriol results in decreased expression of IGFBP5 mRNA | CTD | PMID:15159206 |
| ethylenediaminetetraacetic acid | decreases degradation | EXP | | 6480464 | Edetic Acid results in decreased degradation of IGFBP5 protein | CTD | PMID:8894652 |
| folic acid | affects expression | ISO | RGD:732384 | 6480464 | Folic Acid affects the expression of IGFBP5 mRNA | CTD | PMID:17320366 |
| genistein | decreases expression | EXP | | 6480464 | Genistein results in decreased expression of IGFBP5 mRNA | CTD | PMID:22504913 |
| hydrogen peroxide | increases expression | ISO | RGD:732384 | 6480464 | Hydrogen Peroxide results in increased expression of IGFBP5 mRNA | CTD | PMID:12414654 |
| isotretinoin | increases expression | ISO | RGD:732384 | 6480464 | Isotretinoin results in increased expression of IGFBP5 mRNA | CTD | PMID:20436886 |
| L-ascorbic acid | multiple interactions | ISO | RGD:732384 | 6480464 | [Tretinoin co-treated with Ascorbic Acid] results in decreased expression of IGFBP5 mRNA | CTD | PMID:16443354 |
| lead diacetate | decreases expression | EXP | | 6480464 | lead acetate results in decreased expression of IGFBP5 mRNA | CTD | PMID:11578147 |
| menadione | increases expression | ISO | RGD:732384 | 6480464 | Vitamin K 3 results in increased expression of IGFBP5 mRNA | CTD | PMID:12414654 |
| methotrexate | increases expression | EXP | | 6480464 | Methotrexate results in increased expression of IGFBP5 mRNA | CTD | PMID:15120968 |
| methoxychlor | multiple interactions | ISO | RGD:10776 | 6480464 | [Estradiol co-treated with Methoxychlor metabolite] results in decreased expression of IGFBP5 mRNA | CTD | PMID:11509743 |
| methoxychlor | decreases expression | ISO | RGD:10776 | 6480464 | Methoxychlor metabolite results in decreased expression of IGFBP5 mRNA | CTD | PMID:11509743 |
| mifepristone | decreases expression | ISO | RGD:732384 | 6480464 | Mifepristone results in decreased expression of IGFBP5 mRNA | CTD | PMID:17584828 |
| N-nitrosodiethylamine | increases expression | ISO | RGD:732384 | 6480464 | Diethylnitrosamine results in increased expression of IGFBP5 mRNA | CTD | PMID:21527772 |
| N-nitrosodimethylamine | increases expression | EXP | | 6480464 | Dimethylnitrosamine results in increased expression of IGFBP5 mRNA | CTD | PMID:17032414 |
| paracetamol | decreases expression | ISO | RGD:10776 | 6480464 | Acetaminophen results in decreased expression of IGFBP5 mRNA | CTD | PMID:18544908 |
| paraquat | increases expression | EXP | | 6480464 | Paraquat results in increased expression of IGFBP5 mRNA | CTD | PMID:18198484 |
| phenobarbital | affects expression | ISO | RGD:10776 | 6480464 | Phenobarbital affects the expression of IGFBP5 mRNA | CTD | PMID:23091169 |
| phenylephrine | decreases expression | EXP | | 6480464 | Phenylephrine results in decreased expression of IGFBP5 mRNA | CTD | PMID:18158353 |
| phenylmethanesulfonyl fluoride | decreases degradation | EXP | | 6480464 | Phenylmethylsulfonyl Fluoride results in decreased degradation of IGFBP5 protein | CTD | PMID:8894652 |
| phorbol 13-acetate 12-myristate | multiple interactions | ISO | RGD:732384 | 6480464 | [Zinc co-treated with Tetradecanoylphorbol Acetate] affects the expression of IGFBP5 mRNA | CTD | PMID:16979875 |
| pirinixic acid | decreases expression | ISO | RGD:10776 | 6480464 | pirinixic acid results in decreased expression of IGFBP5 mRNA | CTD | PMID:20059764 |
| pirinixic acid | increases expression | EXP | | 6480464 | pirinixic acid results in increased expression of IGFBP5 mRNA | CTD | PMID:12832660 |
| pirinixic acid | multiple interactions | ISO | RGD:10776 | 6480464 | PPARA protein promotes the reaction [pirinixic acid results in decreased expression of IGFBP5 mRNA] | CTD | PMID:20059764 |
| progesterone | decreases expression | ISO | RGD:732384 | 6480464 | Progesterone results in decreased expression of IGFBP5 mRNA | CTD | PMID:18070364 |
| propiconazole | decreases expression | ISO | RGD:10776 | 6480464 | propiconazole results in decreased expression of IGFBP5 mRNA | CTD | PMID:21278054 |
| rel-(3R,5S)-fluvastatin | multiple interactions | ISO | RGD:732384 | 6480464 | [zoledronic acid co-treated with fluvastatin] results in increased expression of IGFBP5 mRNA | CTD | PMID:16996129 |
| resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of IGFBP5 mRNA | CTD | PMID:19228061 |
| resveratrol | multiple interactions | ISO | RGD:732384 | 6480464 | [Coumestrol co-treated with resveratrol] results in decreased expression of IGFBP5 mRNA | CTD | PMID:19167446 |
| resveratrol | decreases expression | ISO | RGD:732384 | 6480464 | resveratrol results in decreased expression of IGFBP5 mRNA | CTD | PMID:15280659 |
| rosiglitazone | multiple interactions | ISO | RGD:10776 | 6480464 | [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of IGFBP5 mRNA; more ... | CTD | PMID:16054899 |
| sirolimus | decreases expression | EXP | | 6480464 | Sirolimus results in decreased expression of IGFBP5 mRNA | CTD | PMID:21865292 |
| tacrolimus hydrate | increases expression | EXP | | 6480464 | Tacrolimus results in increased expression of IGFBP5 mRNA | CTD | PMID:21865292 |
| tamoxifen | affects expression | ISO | RGD:732384 | 6480464 | Tamoxifen affects the expression of IGFBP5 mRNA | CTD | PMID:14699072 |
| tamoxifen | increases response to substance | ISO | RGD:732384 | 6480464 | IGFBP5 protein results in increased susceptibility to Tamoxifen | CTD | PMID:20354179 |
| tert-butyl hydroperoxide | increases expression | ISO | RGD:732384 | 6480464 | tert-Butylhydroperoxide results in increased expression of IGFBP5 mRNA | CTD | PMID:12414654 |
| testosterone | multiple interactions | EXP | | 6480464 | Testosterone inhibits the reaction [Dexamethasone results in decreased expression of IGFBP5 mRNA] | CTD | PMID:20032058 |
| tetrachloromethane | increases expression | EXP | | 6480464 | Carbon Tetrachloride results in increased expression of IGFBP5 mRNA | CTD | PMID:17032414 |
| theophylline | decreases expression | ISO | RGD:732384 | 6480464 | Theophylline results in decreased expression of IGFBP5 mRNA | CTD | PMID:16083514 |
| trans-resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of IGFBP5 mRNA | CTD | PMID:19228061 |
| trans-resveratrol | multiple interactions | ISO | RGD:732384 | 6480464 | [Coumestrol co-treated with resveratrol] results in decreased expression of IGFBP5 mRNA | CTD | PMID:19167446 |
| trans-resveratrol | decreases expression | ISO | RGD:732384 | 6480464 | resveratrol results in decreased expression of IGFBP5 mRNA | CTD | PMID:15280659 |
| trimellitic anhydride | decreases expression | ISO | RGD:10776 | 6480464 | trimellitic anhydride results in decreased expression of IGFBP5 mRNA | CTD | PMID:19042947 |
| troglitazone | increases expression | ISO | RGD:732384 | 6480464 | troglitazone results in increased expression of IGFBP5 mRNA | CTD | PMID:19140230 |
| vanadium atom | increases expression | ISO | RGD:732384 | 6480464 | Vanadium results in increased expression of IGFBP5 mRNA | CTD | PMID:19000753 |
| vanadium(0) | increases expression | ISO | RGD:732384 | 6480464 | Vanadium results in increased expression of IGFBP5 mRNA | CTD | PMID:19000753 |
| vancomycin | increases expression | ISO | RGD:10776 | 6480464 | Vancomycin results in increased expression of IGFBP5 mRNA | CTD | PMID:18930951 |
| zinc atom | multiple interactions | ISO | RGD:732384 | 6480464 | [Zinc co-treated with Tetradecanoylphorbol Acetate] affects the expression of IGFBP5 mRNA | CTD | PMID:16979875 |
| zinc atom | decreases expression | EXP | | 6480464 | Zinc deficiency results in decreased expression of IGFBP5 mRNA | CTD | PMID:20128680 |
| zinc atom | decreases degradation | EXP | | 6480464 | Zinc results in decreased degradation of IGFBP5 protein | CTD | PMID:8894652 |
| zinc(0) | multiple interactions | ISO | RGD:732384 | 6480464 | [Zinc co-treated with Tetradecanoylphorbol Acetate] affects the expression of IGFBP5 mRNA | CTD | PMID:16979875 |
| zinc(0) | decreases expression | EXP | | 6480464 | Zinc deficiency results in decreased expression of IGFBP5 mRNA | CTD | PMID:20128680 |
| zinc(0) | decreases degradation | EXP | | 6480464 | Zinc results in decreased degradation of IGFBP5 protein | CTD | PMID:8894652 |
| zoledronic acid | multiple interactions | ISO | RGD:732384 | 6480464 | [zoledronic acid co-treated with fluvastatin] results in increased expression of IGFBP5 mRNA | CTD | PMID:16996129 |